Clinical trial · Interventional
The Application Value of Spectral CT in the Accurate Staging of Breast Cancer
NCT06977412CI-TRIAL-00089918not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Adenocarcinoma | Breast Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| To explore the value of spectral CT in the diagnosis and treatment of breast cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- The application value of spectral CT in the accurate staging of breast cancer
- description
- Prospectively collect medical images and clinical data related to breast cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of breast cancer. Patients diagnosed with breast cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of breast cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
- interventionNames
- Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of breast cancer
Primary outcomes (1)
- measure
- Pathological TNM staging
- timeFrame
- 1 day
- description
- Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * (a) Chest quark energy spectrum CT examination was performed within 1 week before treatment * (b) Age ≥ 18 * (c) Suspected breast cancer patients * (d) Patients who signed informed consent Exclusion Criteria: * (a) Severe cardiac, pulmonary and renal insufficiency * (b) Allergic to iodine contrast media * (c) Unable to cooperate to complete CT examination * (d) Quark spectrum CT image is poor and cannot be used * (e) Male, pregnant and lactating female * (f) Combined with other tumor history * (g) Incomplete clinical and pathological data * (h) Pathologically confirmed non breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.